ATTR Webinar 03-09-2024

Описание: Amyloidosis Support Groups webinar on ATTR amyloidosis recorded on March 9, 2024.
Moderated by ASG President Muriel Finkel.

Speakers
Tony Urey, MD, Cardiologist, Assistant Professor of Medicine, UC San Diego School of Medicine, La Jolla, CA
Chafic Karam, MD, Neurologist, Associate Professor of Neurology, University of Pennsylvania, Philadelphia, PA
Jonathan Wall, PhD, Professor, University of Tennessee Graduate School of Medicine, Knoxville, TN
Paula Schmitt, Executive Director, Amyloidosis Support Groups
*Gabriela Tamariz, MD, Medical Science Liaison, Alnylam Pharmaceuticals, Cambridge, MA
*Adam Castaño, MD, MS, Vice President, Global Clinical Development, ATTR Amyloidosis, BridgeBio Pharma, New York, NY
*Hannah Pope, PharmD, MHA, Sr. Medical Science Liaison, BridgeBio Pharma, St. Louis, MO
*Liron Walsh, MD, Head of Development, In Vivo Programs, Intellia Therapeutics, Inc., Cambridge, MA
*Sidsel Høier Gamborg Møller, MD, PhD, Global Medical Manager, Novo Nordisk, Copenhagen, Denmark
*Alyssa A. Hawranko, PhD, Executive Medical Science Liaison, ATTR – Amyloidosis, US Medical Affairs, AstraZeneca, LP
*Cristina Quarta, MD, PhD, Senior Medical Director, Alexion, AstraZeneca Rare Disease, Boston, MA
*Lori Baylor, PhD, Medical Director – Rare Cardiology, US Medical Affairs, Rare Disease, Pfizer Inc., Boston, MA

Chapters
0:00 Welcome and Speaker Introductions
3:09 ATTR Treatment Chart
3:30 Dr. Tony Urey, Current FDA Approved Treatments for ATTR Amyloidosis
21:31 Dr. Chafic Karam, hATTR Polyneuropathy Treatments
42:15 Dr. Tony Urey, Drugs in Clinical Trials (silencers)
59:00 Q&A with Drs. Urey, Karam
1:17:46 Paula Schmitt, Financial Assistance Update
1:26:11 Dr. Tony Urey, Investigational and Anti-fibril Therapies
1:38:17 Q&A 2 with Drs. Urey, Karam
1:44:47 Dr. Jon Wall, Diagnosing Cardiac Amyloid using 99mTc-p5+14 SPECT/CT Imaging
1:59:50 Muriel Finkel & Dr. Urey on BridgeBio ACT-Early trial, use of Tafamidis in BridgeBio ATTRibute-CM study
2:01:44 Muriel Finkel questioning whether pacemakers exclude participants from enrolling in ATTR trials (answer: they usually don't)

This webinar video has been edited for content and time.
Please note that the presentations from pharmaceutical representatives, plus certain Q&A participation, have been excluded from this recording because they were only authorized for use during the live webinar and have not been authorized for post-webinar publication and distribution.